In Vivo Characterization of Changes in Glycine Levels Induced by GlyT1 Inhibitors

Annals of the New York Academy of Sciences

Volumn 1003, Issue , 2003, Pages 412-414

  Johnson, Kirk W ^a   Clemens Smith, Amy ^a   Nomikos, George ^a   Davis, Richard ^a   Phebus, Lee ^a   Shannon, Harlan ^a   Love, Patrick ^a   Perry, Ken ^a   Katner, Jason ^a   Bymaster, Frank ^a   Yu, Hong ^a   Hoffman, Beth J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Glycine level changes; GlyT1 inhibitors; Schizophrenia

Indexed keywords

ALANINE; ALX 5407; GLUTAMIC ACID; GLUTAMINE; GLYCINE; GLYCINE RECEPTOR ANTAGONIST; ORG 24461; SERINE; TAURINE; THREONINE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; CELL LEVEL; CONFERENCE PAPER; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; NONHUMAN; RAT;

ANIMALIA;

EID: 9144238225     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1300.039     Document Type: Conference Paper

References (6)

1. JAVITT, D.C. & S.R. ZUKIN. 1991. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148: 1301-1308.
2. JAVITT, D.C. et al. 1994. Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry 151: 1234-1236.
3. HERESCO-LEVY, U. et al. 1999. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry 56: 29-36.
4. TSAI, G.E. et al. 1999. D-serine added to clozapine for the treatment of schizophrenia. Am. J. Psychiatry 156: 1822-1825.
5. GOFF, D.C. et al. 1999. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch. Gen. Psychiatry 56: 21-27.
6. BOROWSKY, B. et al. 1993. Two glycine transporter variants with distinct localization in the CNS and peripheral tissues are encoded by a common gene. Neuron 10: 851-863.